Engagement
Oct 10, 2025

Report: Inspire Leads Charge to Prevent Abortion Pill Distribution

Abortion pill distribution has quietly become one of the most pressing moral, legal, and financial challenges facing America's largest pharmacy chains.
Report: Inspire Leads Charge to Prevent Abortion Pill Distribution

NEW REPORT: Inspire Leads Charge to Prevent Abortion Pill Distribution


Abortion pill distribution has quietly become one of the most pressing moral, legal, and financial challenges racing America's largest pharmacy chains.

Inspire has been engaging with Costco and other major retail pharmacies since the FDA removed the in-person dispensing requirement for the abortion drug mifepristone.

In the attached report you will find these results:

  • 3 out of 5 major retail pharmacies engaged changed direction and decided NOT to dispense mifepristone
  • Citizens, investors, partners, legislators, and Inspire combine efforts to voice concerns and ensure pharmacies understand the risks of dispensing mifepristone
  • Ongoing engagement efforts as the abortion pill challenge continues

We encourage you to read the report and get involved!

Inspire Engagement Report – Mifepristone

Take a look

No items found.
Share this article
*Advisory Services are offered through Inspire Investing, LLC, a Registered Investment Adviser with the SEC. All expressions of opinion are subject to change. This article is distributed for educational purposes, and it is not to be construed as an offer, solicitation, recommendation, or endorsement of any particular security, products, or services. Investors should talk to their financial advisor prior to making any investment decision.

This article is intended solely for use with sophisticated investors, financial professionals, or institutional clients who are familiar with the limitations of financial projections and forward-looking investment models. It is not intended for retail distribution.

All return expectations, capital market assumptions, and hypothetical portfolio outcomes presented are illustrative, based on proprietary models and current market conditions as of the date noted. These projections are not guarantees of future performance, and actual results may differ materially due to various risks and uncertainties, including changes in market conditions, interest rates, inflation, and geopolitical events.Hypothetical performance results have inherent limitations and are based on assumptions that may not reflect actual trading or investor experience. These projections do not represent actual client accounts, nor are they intended to indicate future performance of any specific strategy or product. Inspire does not represent that any account will achieve results similar to those shown.

The strategic portfolio allocations discussed may include investments in proprietary Exchange Traded Funds (ETFs) advised by Inspire Investing, LLC. Because Inspire receives management fees from these funds, a conflict of interest exists. Inspire seeks to mitigate this conflict through policies and procedures designed to ensure that recommendations are made in the best interest of clients and based on their unique objectives and risk tolerance. Additional information about this conflict is available in Inspire’s Form ADV Part 2A, available at www.adviserinfo.sec.gov.

Investment decisions should be made based on individual goals, time horizons, and risk tolerance. No portion of this article should be interpreted as personalized investment, legal, or tax advice. Please consult a qualified financial professional before implementing any investment strategy.
Advisory services are offered through Inspire Investing, LLC, a Registered Investment Adviser with the SEC. All expressions of opinion are subject to change without notice and are provided for informational purposes only. Nothing in this article should be construed as an offer, solicitation, recommendation, or endorsement of any particular security, strategy, or investment product. Investing involves risk, including the potential loss of principal. Please consult your financial advisor before making any investment decision. Inspire Investing integrates biblical principles into its investment philosophy through a Biblically Responsible Investing (BRI) approach. This values-based methodology reflects Inspire's interpretation of Scripture and may not align with the views or beliefs of all investors.
This content is provided for educational and informational purposes only and should not be considered personalized investment advice. Inspire does not provide legal, tax, or accounting advice. Please consult your own advisor regarding your specific situation.
Inspire's engagement with public companies is part of its Biblically Responsible Investing (BRI) philosophy and aims to promote biblical values through corporate dialogue. Engagement outcomes are not guaranteed and may not directly impact investment returns. Shareholder advocacy is based on Inspire's internal values and may not reflect those of every investor. This article is not intended to solicit or request shareholder votes, nor is it filed as proxy material with the SEC. Any commentary related to proxy proposals reflects the author’s opinion and is not a recommendation to act.
Approval Code:
86ac1kph6
Envelope Icon
Subscribe to the Inspire Investing blog
Get the latest cutting edge thought leadership and research on impact investing, biblically responsible investing (BRI) and the value of biblical principles in business and life.
Latest in
Engagement
All Articles
Start investing today
Start biblically responsible investing today
Our Services
Inspire featured in
Wall Street JournalNew York TimesBarronsBusiness InsiderRecruitersYahoo!BloombergFinancial Times
(877) 658-9473inspire@inspireinvesting.com
Report: Inspire Leads Charge to Prevent Abortion Pill Distribution
Engagement
Oct 10, 2025

Report: Inspire Leads Charge to Prevent Abortion Pill Distribution

Abortion pill distribution has quietly become one of the most pressing moral, legal, and financial challenges facing America's largest pharmacy chains.
inspireinvesting.com/post/
inspire-leads-charge-to-prevent-abortion-pill-distribution

NEW REPORT: Inspire Leads Charge to Prevent Abortion Pill Distribution


Abortion pill distribution has quietly become one of the most pressing moral, legal, and financial challenges racing America's largest pharmacy chains.

Inspire has been engaging with Costco and other major retail pharmacies since the FDA removed the in-person dispensing requirement for the abortion drug mifepristone.

In the attached report you will find these results:

  • 3 out of 5 major retail pharmacies engaged changed direction and decided NOT to dispense mifepristone
  • Citizens, investors, partners, legislators, and Inspire combine efforts to voice concerns and ensure pharmacies understand the risks of dispensing mifepristone
  • Ongoing engagement efforts as the abortion pill challenge continues

We encourage you to read the report and get involved!

Inspire Engagement Report – Mifepristone

inspireinvesting.com/post/
inspire-leads-charge-to-prevent-abortion-pill-distribution